Payment overview · 2025
General Payments
$23.46
1 reported records · 1 companies
Healthcare provider profile · identity verified
Rigel Galera, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · PORT HURON, MI · NPI 1023297967
Verified facts
What the public records show
CMS Open Payments records show Rigel Galera, M.D. received $23.46 in general payments during 2025 across 1 reported records.
Lilly USA, LLC accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 1 associated product.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $23.46 | 100.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $23.46 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $23.46 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 485 | 58 |
| Atorvastatin Calcium | Atorvastatin Calcium | 416 | 57 |
| Omeprazole | Omeprazole | 340 | 49 |
| Furosemide | Furosemide | 336 | 47 |
| Escitalopram Oxalate | Escitalopram Oxalate | 303 | 37 |
| Potassium Chloride | Potassium Chloride | 290 | 41 |
| Losartan Potassium | Losartan Potassium | 254 | 36 |
| Metoprolol Succinate | Metoprolol Succinate | 239 | 31 |
| Tamsulosin Hcl | Tamsulosin Hcl | 210 | 26 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 204 | 20 |
| Trazodone Hcl | Trazodone Hcl | 202 | 24 |
| Amlodipine Besylate | Amlodipine Besylate | 190 | 28 |
| Hydrochlorothiazide | Hydrochlorothiazide | 176 | 21 |
| Famotidine | Famotidine | 174 | 29 |
| Sertraline Hcl | Sertraline Hcl | 170 | 22 |
| Mirtazapine | Mirtazapine | 168 | 24 |
| Allopurinol | Allopurinol | 167 | 24 |
| Simvastatin | Simvastatin | 166 | 16 |
| Buspirone Hcl | Buspirone Hcl | 165 | 25 |
| Lisinopril | Lisinopril | 145 | 21 |
| Quetiapine Fumarate | Quetiapine Fumarate | 144 | 20 |
| Gabapentin | Gabapentin | 131 | 23 |
| Metoprolol Tartrate | Metoprolol Tartrate | 129 | 18 |
| Montelukast Sodium | Montelukast Sodium | 126 | 13 |
| Eliquis | Apixaban | 124 | 18 |
| Meloxicam | Meloxicam | 122 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 112 | 16 |
| Metformin Hcl Er | Metformin Hcl | 110 | 14 |
| Alprazolam | Alprazolam | 106 | 25 |
| Memantine Hcl | Memantine Hcl | 99 | 13 |
| Pantoprazole Sodium | Pantoprazole Sodium | 97 | 15 |
| Midodrine Hcl | Midodrine Hcl | 95 | 14 |
| Myrbetriq | Mirabegron | 91 | 13 |
| Clonidine Hcl | Clonidine Hcl | 85 | suppressed |
| Risperidone | Risperidone | 84 | 11 |
| Methenamine Hippurate | Methenamine Hippurate | 79 | suppressed |
| Spironolactone | Spironolactone | 77 | 15 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 75 | 20 |
| Aripiprazole | Aripiprazole | 73 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 69 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 69 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 68 | suppressed |
| Chlorthalidone | Chlorthalidone | 68 | suppressed |
| Olanzapine | Olanzapine | 68 | suppressed |
| Januvia | Sitagliptin Phosphate | 66 | suppressed |
| Carvedilol | Carvedilol | 65 | suppressed |
| Temazepam | Temazepam | 62 | suppressed |
| Loperamide | Loperamide Hcl | 59 | 15 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 59 | 11 |
| Sucralfate | Sucralfate | 59 | suppressed |
| Metformin Hcl | Metformin Hcl | 55 | 12 |
| Naproxen | Naproxen | 55 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 54 | 16 |
| Lorazepam | Lorazepam | 54 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 52 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 52 | suppressed |
| Glipizide | Glipizide | 50 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 50 | 13 |
| Divalproex Sodium | Divalproex Sodium | 49 | suppressed |
| Ibuprofen | Ibuprofen | 45 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 44 | 18 |
| Baclofen | Baclofen | 44 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 44 | 39 |
| Bupropion Xl | Bupropion Hcl | 42 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 42 | suppressed |
| Primidone | Primidone | 41 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 40 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 40 | suppressed |
| Metolazone | Metolazone | 40 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 40 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 39 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 38 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 38 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 38 | 13 |
| Ozempic | Semaglutide | 38 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 37 | 32 |
| Benztropine Mesylate | Benztropine Mesylate | 36 | suppressed |
| Lamotrigine | Lamotrigine | 36 | suppressed |
| Cholestyramine Light | Cholestyramine | 34 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 33 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 33 | 13 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 32 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 32 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 32 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 31 | 13 |
| Lactulose | Lactulose | 31 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 31 | 13 |
| Levetiracetam | Levetiracetam | 31 | suppressed |
| Azithromycin | Azithromycin | 29 | 27 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 29 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 28 | 26 |
| Enalapril Maleate | Enalapril Maleate | 28 | suppressed |
| Torsemide | Torsemide | 28 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 28 | suppressed |
| Methylprednisolone | Methylprednisolone | 27 | 25 |
| Atenolol | Atenolol | 26 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 26 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 25 | suppressed |
| Haloperidol | Haloperidol | 25 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 25 | suppressed |
| Trulicity | Dulaglutide | 25 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 24 | suppressed |
| Methimazole | Methimazole | 24 | suppressed |
| Nystatin | Nystatin | 24 | 12 |
| Propranolol Hcl Er | Propranolol Hcl | 24 | suppressed |
| Cephalexin | Cephalexin | 23 | 21 |
| Paroxetine Hcl | Paroxetine Hcl | 23 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 23 | suppressed |
| Prednisone | Prednisone | 23 | suppressed |
| Ursodiol | Ursodiol | 23 | suppressed |
| Glimepiride | Glimepiride | 22 | suppressed |
| Topiramate | Topiramate | 21 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 20 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 19 | suppressed |
| Carbamazepine | Carbamazepine | 19 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 19 | suppressed |
| Celecoxib | Celecoxib | 19 | suppressed |
| Jardiance | Empagliflozin | 19 | suppressed |
| Ssd | Silver Sulfadiazine | 19 | suppressed |
| Tradjenta | Linagliptin | 19 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 18 | suppressed |
| Digoxin | Digoxin | 18 | suppressed |
| Novolog Flexpen | Insulin Aspart | 18 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 18 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 17 | suppressed |
| Dexamethasone | Dexamethasone | 17 | suppressed |
| Haloperidol Decanoate | Haloperidol Decanoate | 17 | suppressed |
| Lacosamide | Lacosamide | 17 | suppressed |
| Lovastatin | Lovastatin | 17 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 17 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 16 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 16 | suppressed |
| Latanoprost | Latanoprost | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 15 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 15 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 15 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 15 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Misoprostol | Misoprostol | 14 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 14 | suppressed |
| Ramipril | Ramipril | 14 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 14 | suppressed |
| Trospium Chloride Er | Trospium Chloride | 14 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Avycaz | Ceftazidime/Avibactam | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 13 | suppressed |
| Synthroid | Levothyroxine Sodium | 13 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 13 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 12 | suppressed |
| Carbamazepine Er | Carbamazepine | 12 | suppressed |
| Dutasteride | Dutasteride | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Glyburide | Glyburide | 12 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 12 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 12 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 12 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 12 | suppressed |
| Constulose | Lactulose | 11 | suppressed |
| Ezetimibe | Ezetimibe | 11 | suppressed |
| Finasteride | Finasteride | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $23.46 · 1 records | Lilly USA, LLC | KISUNLA | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error